You can buy Lorbrexen at the lowest price at Nextgen.ooo online pharmacy. Lorlatinib is an anaplastic lymphoma kinase inhibitor used to treat metastatic ALK+ non-small cell lung cancer. Non-small cell lung cancer (NSCLC) accounts for up to 85% of lung cancer cases worldwide and remains a particularly difficult to treat condition. Anaplastic lymphoma kinase (ALK) gene rearrangement is a genetic change that leads to the development of NSCLC in a number of patients. ALK is a naturally occurring endogenous tyrosine kinase receptor that plays an important role in brain development and induces the activity of various specific neurons in the nervous system. Lorlatinib is a kinase inhibitor with in vitro activity against ALK and a number of other receptor tyrosine kinase-related targets, including ROS1, TYK1, FER, FPS, TRKA, TRKB, TRKC, FAK, FAK2, and ACK. Lorlatinib has demonstrated in vitro activity against several mutant forms of the ALK enzyme, including mutations found in tumors during disease progression on crizotinib and other ALK inhibitors.
 
Various clinical trials conducted with lorlatinib have demonstrated its tumor regression efficacy in ALK-positive patients with metastatic NSCLC who experience tumor progression despite treatment with various first- and second-generation tyrosine kinase inhibitors, such as crizotinib, alectinib, or ceritinib. The ability of lorlatinib to cross the blood-brain barrier also facilitates the treatment of advanced brain metastases. Lorlatinib is indicated for the treatment of patients with metastatic or locally advanced ALK-positive non-small cell lung cancer as a first-line treatment or after disease progression following treatment with brigatinib, alectinib or ceritinib.